GALT — Galectin Therapeutics Share Price
0.000.00%
Last trade - 00:00- $140.45m
- $199.36m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -281.95% | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 36.32 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Galectin Therapeutics, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company's lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the United States Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The Company's additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies.
Directors
- Richard Uihlein NEC (75)
- Joel Lewis PRE (51)
- Jack Callicutt CFO (53)
- Eliezer Zomer EVP (74)
- J. Rex Horton VPR (51)
- Pol Boudes OTH (64)
- Harold Shlevin DRC (71)
- Gilbert Amelio IND (78)
- James Czirr IND (67)
- Kary Eldred IND (47)
- Kevin Freeman IND (59)
- Gilbert Omenn IND (79)
- Marc Rubin IND (66)
- Elissa Schwartz IND (50)
- Richard Zordani IND (48)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- January 26th, 2001
- Public Since
- September 4th, 2002
- No. of Shareholders
- 138
- No. of Employees
- 14
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 62,148,134
- Address
- SUITE 240, NORCROSS, 30071
- Web
- https://galectintherapeutics.com/
- Phone
- +1 6786203186
- Auditors
- Cherry Bekaert LLP
Upcoming Events for GALT
Q3 2024 Galectin Therapeutics Inc Earnings Release
Galectin Therapeutics Inc Annual Shareholders Meeting
Similar to GALT
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Galectin Therapeutics share price?
As of Today at 20:48 UTC, shares in Galectin Therapeutics are trading at $2.34. This share price information is delayed by 15 minutes.
How has the Galectin Therapeutics share price performed this year?
Shares in Galectin Therapeutics last closed at $2.34 and the price had moved by +65.96% over the past 365 days. In terms of relative price strength the Galectin Therapeutics share price has outperformed the S&P500 Index by +32.06% over the past year.
What are the analyst and broker recommendations for Galectin Therapeutics?
The overall consensus recommendation for Galectin Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Galectin Therapeutics dividend yield?
Galectin Therapeutics does not currently pay a dividend.
Does Galectin Therapeutics pay a dividend?
Galectin Therapeutics does not currently pay a dividend.
When does Galectin Therapeutics next pay dividends?
Galectin Therapeutics does not currently pay a dividend.
How do I buy Galectin Therapeutics shares?
To buy shares in Galectin Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Galectin Therapeutics?
As of the previous close price of $2.34, shares in Galectin Therapeutics had a market capitalisation of $145.43m.
Where are Galectin Therapeutics shares listed?
Here are the trading details for Galectin Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: GALT
What kind of share is Galectin Therapeutics?
Based on an overall assessment of its quality, value and momentum Galectin Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Galectin Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Galectin Therapeutics is $11.00. That is 370.09% above the last closing price of $2.34.
Analysts covering Galectin Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.66 for the next financial year.
What is the trend in the Galectin Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Galectin Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +15.51%.
As of the last closing price of $2.34, shares in Galectin Therapeutics were trading +3.86% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Galectin Therapeutics PE Ratio?
The Galectin Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.34.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Galectin Therapeutics?
Galectin Therapeutics' management team is headed by:
- Richard Uihlein - NEC
- Joel Lewis - PRE
- Jack Callicutt - CFO
- Eliezer Zomer - EVP
- J. Rex Horton - VPR
- Pol Boudes - OTH
- Harold Shlevin - DRC
- Gilbert Amelio - IND
- James Czirr - IND
- Kary Eldred - IND
- Kevin Freeman - IND
- Gilbert Omenn - IND
- Marc Rubin - IND
- Elissa Schwartz - IND
- Richard Zordani - IND